XSC
ACRS icon

X-Square Capital’s Aclaris Therapeutics ACRS Stock Holding History

X-Square Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16,000
Closed -$252K – 155
2022
Q4 		$252K Hold
16,000
– – 0.14% 132
2022
Q3 		$252K Hold
16,000
– – 0.16% 125
2022
Q2 		$223K Hold
16,000
– – 0.13% 131
2022
Q1 		$276K Hold
16,000
– – 0.14% 127
2021
Q4 		$233K Hold
16,000
– – 0.12% 134
2021
Q3 		$288K Hold
16,000
– – 0.15% 125
2021
Q2 		$281K Buy
+16,000
New +$363K 0.13% 122

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

X-Square Capital's ACRS Position: Q1 2023 in Review

X-Square Capital sold out of Aclaris Therapeutics (ACRS) in Q1 2023, closing a stake of 16,000 shares — an estimated $252K sold.

X-Square Capital first reported a position in ACRS in Q2 2021 and held it in 7 quarters. The position peaked at $288K in Q3 2021. 148 funds tracked by Wall St. Rank hold ACRS as of Q1 2023.

  • X-Square Capital reported no remaining Aclaris Therapeutics position as of Q1 2023 after selling out during the quarter.
  • X-Square Capital sold 16,000 Aclaris Therapeutics shares in Q1 2023, an estimated $252K.
  • X-Square Capital first reported a position in Aclaris Therapeutics in Q2 2021 and held it in 7 quarters.
  • X-Square Capital's Aclaris Therapeutics position peaked at $288K in Q3 2021.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2023.

Based on X-Square Capital's 13F filing for Q1 2023, filed 11 May 2023.